Advancing Gene Therapy with Higher Confidence
Bringing human biology into early gene therapy development can be easily achieved
by using the iPSC-based Ncardia platform
We help you select the most promising gene therapy candidate earlier with our dependable iPSC-platform
Despite the great potential of gene therapies, only a few drugs have received market approval from regulators. To effectively bring next-gen gene therapies from bench to bedside, there is a strong need for alternative testing platforms that recapitulate human pathophysiology and help making accurate predictions.
Human induced pluripotent stem cells (iPSC)-derived models are a promising alternative to support and supplement animal testing. They recapitulate disease hallmarks in vitro and can be integrated in discovery to facilitate the selection of the most promising candidates, saving resources and reducing the translational gap.
Benefits of Ncardia Solutions
Customized to your specifications
Model the phenotype
of your interest
Predictive responses
Testing on relevant
human biology
Gaining Confidence in Essential Stages
What we can do for you
With the Ncardia platform, we facilitate your decision-making steps during gene therapy development by integrating human models and clinically relevant readouts.
- Test AAV selectivity and toxicity
- Quantify transgene expression
- Determine AAV transduction efficiency
- Study AAV efficacy to rescue disease phenotypes
We harness our expertise in iPSC differentiation to create tailor-made models and screening assays for AAV testing. We deliver consistent and reliable results, allowing you to identify the most promising vectors at the earliest stages of development.
Discover more about our solutions for gene therapy
Leverage our extended expertise supporting the development of ground-breaking gene therapies for pharma and biotech companies.
Contact Us
If you're ready to explore how to accelerate the development of your gene therapy with our leading iPSC-based platform, we'd welcome the opportunity to introduce you to Ncardia.